Skip to main content

Advertisement

SpringerLink
Log in

Comparison of calcium and alfacalcidol supplement in the prevention of osteopenia after kidney transplantation

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

The aim of this observational study was to compare the effect of calcium and alfacalcidol supplementation on the regression of hyperparathyroidism and on prevention of osteopenia in patients up to 3 years after renal transplantation. Two historical cohorts were compared for that purpose. One hundred and fifty-nine patients received calcium carbonate supplement (group 1), while 81 patients were treated with alfacalcidol (group 2). Serum Ca, phosphate (P), Mg, creatinine, alkaline phosphatase (AP) and parathyroid hormone (PTH) levels were determined before and after transplantation in the two groups, for 3 years. Femoral neck and lumbar spine bone mineral density (BMD) was measured only at 3 and 6 months and 1, 2 and 3 years after transplantation. At baseline there was no difference in age or sex ratio, but prevalence in post-menopausal women was higher in group 1 (6.9% versus 1.2%). Duration on dialysis was comparable but prevalence of interstitial and undetermined nephropathies was higher in group 1. Baseline serum concentrations of PTH, Ca and P were comparable in both groups. After transplantation, plasma creatinine decreased to comparable levels in both groups. Immunosuppression by triple therapy was more prevalent in group 2, so that cumulative dose of steroid was higher in group 1, especially at 1 month because of higher incidence of acute rejections (51% versus 13%). Mean intact PTH levels decreased in both groups, from 18 pmol/l to 8.4 and 7.9 at 3 years, but the decrease was significantly greater with alfacalcidol at 6 and 12 months. At 3 months, BMD were comparable at both sites. From 3 months to 3 years after kidney transplantation, mean lumbar spine BMD significantly increased from 0.963 to 1.054 g/cm2 in group 1, whereas there was no significant decrease (1.048 to 1.006 g/cm2) in group 2, the difference in changes being significant (P<0.05). Femoral neck BMD was not significantly increased in either group (0.932 to 0.993 g/cm2 in group 1, and 0.850 to 0.907 g/cm2 in group 2). Expressed as percentages, these changes were +9.4% and –4% for lumbar BMD and +6.5% and +6.7% for femoral neck, for groups 1 and 2, respectively. Prevalence of osteopenia was not significantly lower at 3 years in group 1 (45% and 51%) than in group 2. During the follow-up period, osteonecrosis was diagnosed in six patients (3.8%) in group 1 and in nine (11%) in group 2. In conclusion, alfacalcidol compared to CaCO3 supplement suppressed hyperparathyroidism more rapidly and strongly. In spite of higher osteopenia risk in the CaCO3 group, lumbar BMD increase was greater and incidence of osteonecrosis higher in this group, suggesting better bone protection with CaCO3 than with alfacalcidol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Almond MK, Kwan JTC, Evans K, Cunningham J (1994) Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 66:52–57

    Google Scholar 

  2. Babarykin D, Adamsone I, Amerika D, Folkmane I, Rozental R (1999) Disorders of calcium metabolism at various times after renal transplantation. Ann Transplant 4:46–53

    Google Scholar 

  3. Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, Bellorin-Font E (2000) Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 36:160–166

    Google Scholar 

  4. Cueto-Manzano AM, Konel S, Huchinson AJ, Crowley V, France MW, Freemont AJ, Adams JE, Mawer B, Gokal R (1999) Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int 55:2021–2029

    Google Scholar 

  5. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH (2000) High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11:1093–1099

    Google Scholar 

  6. Pichette V, Bonnerdeaux A, Prudhomme L, Gagne M, Cardinal J, Quimet D (1996) Long-term bone loss in kidney transplant recipients. A cross-sectional and longitudinal study. Am J Kidney Dis 28:105–114

    Google Scholar 

  7. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD (1991) Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544–550

    Google Scholar 

  8. Torres A, Rodriguez AP, Conception MT, Garcia S, Rufino M, Martin B, Perez L, Machado M, Bonis E, Losada M, Hernandez D, Lorenzo V (1998) Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 13:94–97

  9. Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Schollmeyer PJ (1995) Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation 59:982–986

    Google Scholar 

  10. Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger PH (1994) Changes in bone mass early after kidney transplantation. J Bone Miner Res 9:1-9

    Google Scholar 

  11. Westeel FP, Mazouz H, Ezaitouni F, Hottelart C, Ivan C, Fardellone P, Brazier M, El-Esper I, Petit J, Achard JM, Pruna A, Fournier A (2000) Cyclosporine bone remodelling effect prevents steroid osteopenia after kidney transplantation. Kidney Int 58:1788–1796

    Google Scholar 

  12. Goffin E, Devogelaer JP, Depresseux G, van-Ypersele-de-Strihou C (2001) Bone mass evolution after renal transplantation. Kidney Int 59:1594–1595

    Google Scholar 

  13. Pazianas M, Phillips ME, MacRae KD, Eastwood JB (1992) Identification of risk factors for radiographic hyperparathyroidism in 422 patients with end-stage renal disease: development of a clinical predictive index. Nephrol Dial Transplant 7:1098–1105

    Google Scholar 

  14. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E (1999) The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65:311–316

    Google Scholar 

  15. Fujita T (1992) Vitamin D in the treatment of osteoporosis. Proc Soc Exp Biol Med 199:394–399

    Google Scholar 

  16. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642

    Google Scholar 

  17. Balsan S, Garabedian M, Larchet M, Gorski AM, Cournot G, Tau C, Bourdeau A, Silve C, Ricour C (1986) Long-term nocturnal calcium infusion can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 77:1661–1667

    Google Scholar 

  18. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, Delling MB (1998) Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139:4391–4396

    Google Scholar 

  19. Kinuta K, Tanaka H, Shinohara M, Kato S, Seino Y (2000) Vitamin D is a negative regulating factor in bone mineralization. J Bone Miner Res 15: S180

  20. Fournier A, Bordier P, Gueris J, Sebert JL, Marie P, Ferriere C, Bedrossian J, De Luca HF (1979) Comparison of alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Kidney Int 15:196–204

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Surgery, University of Debrecen, Debrecen, Hungary

    C. Berczi, L. Asztalos, Z. Kincses, A. Balogh, L. Lőcsey, G. Balázs & G. Lukács

  2. Department of Gynecology, University of Debrecen, Debrecen, Hungary

    A. Balogh

  3. 10th Dialysis Centre of Eurocare, Debrecen, Hungary

    L. Lőcsey

  4. Késmárk str.7/C, 4029, Debrecen, Hungary

    C. Berczi

Authors
  1. C. Berczi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Asztalos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z. Kincses
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Balogh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Lőcsey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Balázs
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Lukács
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Berczi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berczi, C., Asztalos, L., Kincses, Z. et al. Comparison of calcium and alfacalcidol supplement in the prevention of osteopenia after kidney transplantation. Osteoporos Int 14, 412–417 (2003). https://doi.org/10.1007/s00198-003-1389-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-003-1389-0

Keywords

Search

Navigation